Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

SenefAS Apr. 9 at 7:22 AM

$GMAB Genmab is still undervalued a this level… $NVO $JNJ $PFE

0 · Reply

Digitalization2026 Apr. 8 at 11:41 PM

$SRXH 🏆 Beating the S&P 500 while most stocks fell is a big deal — that’s real performance, not noise 📈 What a lot of people miss: the dividend talk is HUGE. If SRXH starts returning cash to holders, you earn money just for holding, on top of share price gains 💰 Look at top dividend stocks for perspective: • Johnson & Johnson pays ~3.5% annually • Exxon Mobil ~3.8% • Apple ~0.6% If SRXH ever pays a meaningful yield tied to profits, that’s extra return beyond capital appreciation. Also worth noting: SRXH chose not to enact a reverse split recently — that reduces dilution overhang and signals management prefers organic price discovery over a cosmetic split that doesn’t change fundamentals. Beating the market + possible dividends + reduced overhang = a narrative most haven’t priced in 🚀 Not financial advice ⚠️ $JNJ $AAPL $XOM $SPY https://www.emjx.ai

1 · Reply

The__short_squeezer Apr. 8 at 9:03 PM

$WMT $ORCL $MU $SNDK $JNJ I was partially right. Even though the regime has not fallen (but I believe it will eventually fall through a civilian process), Trump and certainly Netanyahu will not do this stupid thing of continuing the war for the long term. Now is the time for the market to calm down and reach new heights. Trump and Netanyahu have proven that they are responsible leaders!

3 · Reply

TechTraderGrok Apr. 8 at 8:19 PM

Bought $JNJ at $240.84. From Grok: "JNJ looks attractive for a long here with bullish analyst notes targeting $250, solid pipeline momentum, and constructive longer-term uptrend ahead of earnings. " https://www.techtrader.ai/grokwall/?post=17637&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

trenddetector Apr. 8 at 6:37 PM

$JNJ Made some updates here. Please share with those in need! "Your path through cancer's complexity. Explore every approved treatment, every open clinical trial, and every option your doctor might not know to mention — all in plain English, all in one place. Browse anonymously. No account required.” https://nimble-frangollo-81ff5e.netlify.app/#

0 · Reply

IN0V8 Apr. 8 at 2:55 PM

$JNJ Opportunity Citigroup raises target price to $285 from $274

0 · Reply

DragonAlgo Apr. 8 at 2:04 PM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-10 | Strike: $260.00 | Type: CALL Option Plan (premium): Entry: $0.05 Stop: $0.04 TP1: $0.07 TP2: $0.09 TP3: $0.12 🔗 https://dragonalgo.com

0 · Reply

KarenLouisa Apr. 8 at 1:42 PM

POLITICAL PORTFOLIO FLOW ALERT Rep. Lloyd Doggett (TX-37) just filed a new disclosure — and the flow is steady, not speculative. These are mostly automatic dividend reinvestments, but the names matter Buys: • $HD – Home Depot (03/26/2026) • $IBM – IBM (03/10/2026) • $JNJ – Johnson & Johnson (03/10/2026) • $PPG – PPG Industries (03/12/2026) What this signals: • Continued accumulation in dividend + blue-chip leaders • Exposure to healthcare ($JNJ), tech/services ($IBM), and cyclical economy plays ($HD, $PPG) • Positions align with sectors tied to tax policy, trade, and economic oversight Key takeaway: This isn’t aggressive trading — it’s consistent long-term capital allocation into cash-flow heavy giants. These names are often seen as “policy-sensitive” and macro-resilient. Smart money or just auto-reinvesting? Either way, these flows don’t go unnoticed… watch how $HD $IBM $JNJ $PPG behave next.

0 · Reply

Wallstfan Apr. 8 at 1:41 PM

$JNJ added on the dip

0 · Reply

NasdaqPulse Apr. 8 at 1:26 PM

$JNJ quietly setting up while the market chases higher-beta names. 👉Click to view @NasdaqPulse for timely updates amid the volatility. This isn’t a hype ticker — it’s a capital preservation + steady growth compounder with a global moat. When volatility spikes, money tends to rotate back into names like this for stability, dividends, and defensive positioning. Price action is coiling… compression often precedes expansion. If we see a breakout with volume, it could mark a shift in institutional positioning. If not, it remains a slow-burn accumulation zone. Boring? Maybe. Powerful over time? Historically, yes. Watching for confirmation — not forcing the trade.

0 · Reply

Buy Johnson & Johnson Ahead of Earnings. The Stock's Run-Up Isn't Over.

Apr 7, 2026, 8:00 AM EDT - 1 day ago

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Mar 30, 2026, 9:14 AM EDT - 9 days ago

Royalty Pharma and J&J partner to develop autoimmune treatment

RPRX

Mar 28, 2026, 10:00 AM EDT - 11 days ago

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Mar 27, 2026, 4:46 PM EDT - 12 days ago

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Mar 27, 2026, 6:31 AM EDT - 12 days ago

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Mar 19, 2026, 1:00 PM EDT - 20 days ago

The Big 3: ORCL, JNJ, SBUX

ORCL SBUX

Mar 19, 2026, 9:35 AM EDT - 20 days ago

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

Mar 18, 2026, 2:23 PM EDT - 21 days ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK LLY

Mar 18, 2026, 1:17 PM EDT - 21 days ago

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Mar 18, 2026, 8:31 AM EDT - 21 days ago

US FDA approves J&J's oral psoriasis pill

Mar 18, 2026, 7:49 AM EDT - 21 days ago

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Mar 16, 2026, 11:00 AM EDT - 23 days ago

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Mar 13, 2026, 12:35 PM EDT - 26 days ago

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Mar 12, 2026, 8:00 AM EDT - 27 days ago

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

$Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line$

Mar 5, 2026, 3:55 PM EST - 4 weeks ago

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Mar 5, 2026, 2:21 PM EST - 4 weeks ago

US FDA approves JNJ's blood cancer drug

Mar 4, 2026, 6:07 PM EST - 5 weeks ago

Johnson & Johnson launches website for direct-to-consumer sales

Mar 3, 2026, 8:03 AM EST - 5 weeks ago

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Mar 2, 2026, 4:30 PM EST - 5 weeks ago

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Feb 26, 2026, 2:30 PM EST - 5 weeks ago

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Feb 24, 2026, 4:03 PM EST - 6 weeks ago

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Feb 23, 2026, 11:35 AM EST - 6 weeks ago

Does JNJ Stock Still Offer Value?

Feb 23, 2026, 10:43 AM EST - 6 weeks ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Feb 23, 2026, 10:28 AM EST - 6 weeks ago

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

Feb 21, 2026, 8:00 AM EST - 6 weeks ago

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Feb 19, 2026, 5:00 PM EST - 6 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Feb 19, 2026, 2:34 PM EST - 6 weeks ago

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Feb 19, 2026, 2:11 PM EST - 6 weeks ago

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

Feb 18, 2026, 10:44 AM EST - 7 weeks ago

Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory

Feb 18, 2026, 10:17 AM EST - 7 weeks ago

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push

Feb 18, 2026, 10:15 AM EST - 7 weeks ago

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

Feb 18, 2026, 7:30 AM EST - 7 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Feb 17, 2026, 8:00 AM EST - 7 weeks ago

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Feb 13, 2026, 4:19 PM EST - 7 weeks ago

Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K

Feb 13, 2026, 4:18 PM EST - 7 weeks ago

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

Feb 13, 2026, 2:43 PM EST - 7 weeks ago

Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial

Feb 13, 2026, 7:00 AM EST - 7 weeks ago

After A 55% Surge, Is JNJ Stock Still A Buy?

Feb 11, 2026, 2:23 PM EST - 2 months ago

NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review

Feb 9, 2026, 4:16 PM EST - 2 months ago

Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference

Feb 6, 2026, 7:00 PM EST - 2 months ago

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

Feb 5, 2026, 1:00 PM EST - 2 months ago

The Big 3: JNJ, XOM, KO

XOM KO

Feb 4, 2026, 1:37 PM EST - 2 months ago

These hot S&P 500 stocks show where investors are heading as they run away from tech

FDX NOC NSC RTX WMT XOM

Feb 3, 2026, 8:47 AM EST - 2 months ago

What's Behind The 50% Surge In JNJ Stock?

Feb 3, 2026, 3:00 AM EST - 2 months ago

Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland

Feb 2, 2026, 4:34 PM EST - 2 months ago

Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference

Jan 30, 2026, 7:19 AM EST - 2 months ago

Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations

Jan 29, 2026, 6:32 PM EST - 2 months ago

US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy

Jan 29, 2026, 12:42 PM EST - 2 months ago

This Winning Fund Pro Likes J&J, Lowe's, and Utility Stocks

LOW

Jan 27, 2026, 3:49 PM EST - 2 months ago

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

SenefAS Apr. 9 at 7:22 AM

$GMAB Genmab is still undervalued a this level… $NVO $JNJ $PFE

0 · Reply

Digitalization2026 Apr. 8 at 11:41 PM

1 · Reply

The__short_squeezer Apr. 8 at 9:03 PM

3 · Reply

TechTraderGrok Apr. 8 at 8:19 PM

0 · Reply

trenddetector Apr. 8 at 6:37 PM

0 · Reply

IN0V8 Apr. 8 at 2:55 PM

$JNJ Opportunity Citigroup raises target price to $285 from $274

0 · Reply

DragonAlgo Apr. 8 at 2:04 PM

0 · Reply

KarenLouisa Apr. 8 at 1:42 PM

0 · Reply

Wallstfan Apr. 8 at 1:41 PM

$JNJ added on the dip

0 · Reply

NasdaqPulse Apr. 8 at 1:26 PM

0 · Reply

GordoHLYK13 Apr. 8 at 1:12 PM

$ABBV $CUE $JNJ I meant to say please read Btw This news isn’t just a headline — it’s structured upside with real future cash flow potential. If the stock holds its gains after 9:30 with strong volume, that’s when institutions and smarter money typically show up and validate the move. 🚀

0 · Reply

RobinCollins1 Apr. 8 at 1:08 PM

$BRK.B $JPM $XOM $JNJ $KO This is Richard Bernstein’s playbook for a slower, more volatile market — and it’s all about defense + cash flow dominance. 🔹 $BRK.B — sitting on ~$200B+ in cash, essentially a fortress when risk assets wobble. 🔹 $JPM — the most resilient mega-bank, still throwing off massive earnings + dividends even in a slowdown. 🔹 $XOM — energy hedge + inflation protection. When oil spikes, cash flow follows. 🔹 $JNJ — healthcare stability + decades of dividend growth = pure defensive alpha. 🔹 $KO — the classic “sleep-well-at-night” stock. 60+ years of dividend hikes. Bernstein’s message is simple: when markets get shaky, own cash flows, not narratives. If growth rolls over, this basket doesn’t just protect — it outperforms.

0 · Reply

GordoHLYK13 Apr. 8 at 12:33 PM

$CUE please PR CUE just laid out a path to $337M+ in milestones plus royalties—that’s not hope, that’s a structured upside pipeline. Big pharma doesn’t write checks like that unless they see real potential. If they keep hitting milestones, this isn’t just a trade—it’s a multi-stage re-rating story waiting to unfold. 🚀 $JNJ $ABBV

0 · Reply

EthelBurkhardt272 Apr. 8 at 11:58 AM

$JNJ steady, defensive, doing exactly what it’s supposed to do

0 · Reply

catacal_ Apr. 8 at 7:47 AM

$JNJ earnings on Tue. Apr. 14 at 6:20 AM. Could see some volatility. See full details: https://www.catacal.com/catalyst/johnson-johnson-earnings-13 Johnson & Johnson will be reporting earnings for the previous quarter. Projected EPS: $2.69 Projected Revenue: $23.44... $SPY $QQQ

0 · Reply

AcceleratorModel Apr. 8 at 6:53 AM

$JNJ got back over 240 but looks weak rn

1 · Reply

TechTraderGrok Apr. 7 at 9:04 PM

Sold $JNJ at $238.8 (-0.5%). From Grok: "Exiting our long from 239.93 on 3/25 as JNJ shows short-term weakness and distribution after failing to hold gains toward 248 resistance, with earnings risk in a week. " https://www.techtrader.ai/grokwall/?post=17615&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

DragonAlgo Apr. 7 at 7:02 PM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-10 | Strike: $237.50 | Type: CALL Option Plan (premium): Entry: $3.73 Stop: $2.68 TP1: $4.84 TP2: $6.33 TP3: $8.94 Volatility regime is active. 🔗 https://dragonalgo.com

0 · Reply

GordoHLYK13 Apr. 7 at 5:48 PM

$CUE $JNJ you can spin it however you want, but facts don’t lie — Cue just secured a $7.5M milestone payment from Boehringer Ingelheim, proving real partnership traction and ongoing value creation. Today’s R&D presentation wasn’t hype — it reinforced progress on CUE-401, a next-gen platform in a massive unmet market, now under new interim CEO leadership focused on execution from $JNJ . Call it what you want… but partnerships, funding, and pipeline progress don’t scream “failure” — they scream momentum. 🚀

0 · Reply

GordoHLYK13 Apr. 7 at 4:27 PM

$CUE $JNJ Buddy You’re calling it failure, but ignoring what actually matters. • **Merck & Co. didn’t walk away from broken science — they walked after getting what they needed: 👉 human validation of the platform That’s exactly what CUE used to pivot. • CUE-101 = oncology signal • Now → CUE-401 = autoimmune (bigger, chronic market) That’s not “starting from scratch” — that’s evolving the platform where the ROI is higher ⸻ • Interim CEO with Johnson & Johnson background 👉 That’s not desperation — that’s Big Pharma execution stepping in ⸻ • “Delisting in 2 weeks” is just wrong Compliance processes take time, extensions exist, and companies don’t host R&D Days + initiate INDs if they’re folding ⸻ 🔥 Old asset didn’t pan out commercially — happens all the time in biotech. Platform got validated — that’s what survives. Now they’re: 👉 Advancing CUE-401 👉 Entering autoimmune 👉 Moving toward IND That’s not a company dying — that’s one repositioning before the next phase.

1 · Reply

GordoHLYK13 Apr. 7 at 4:21 PM

$CUE Shortie @SirDuncan You’re mixing old $CUE with new $CUE. • CEO with Johnson & Johnson background stepping in = execution, not a red flag • IND “not guaranteed” — sure, but trials don’t take until 2027 if cleared… it’s months, not years • CUE-101 didn’t “fail” — it validated the platform in humans Now they’re pivoting to CUE-401 (autoimmune = bigger market) 👉 This isn’t the same company you’re criticizing. $JNJ

1 · Reply

GordoHLYK13 Apr. 7 at 4:02 PM

$CUE $CUE just flipped the switch today. CUE-401 showing immune reset potential… Doctors backing the science… CEO with Big Pharma pedigree… And now: 👉 IND officially being initiated = human trials next That’s the line between a $30M biotech and a re-rated clinical-stage company. ➡️ Market still pricing preclinical risk… while the company is stepping into human trials + autoimmune expansion That’s how billion-dollar runs quietly begin. $JNJ

1 · Reply

Market Cap	574.24B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	22.31
Forward PE	21.06
Profit Margin	28.46%
Debt to Equity Ratio	0.48

Volume	8,771,100
Avg Vol	8,443,632
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	56%
Beta	0.34
Analysts	Strong Sell
Price Target	$243.16